Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)

Bicara Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• In Q1 2026, Research & Development fell 98.48% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at -$34.2 million (down 1325.37% YoY), while the FY2024 annual figure was $8.2 million, down 73.15% from the prior year.
• Research & Development for Q1 2026 stood at $100000.0, up from -$92.1 million in the prior quarter.
• The five-year high for Research & Development was $33.0 million in Q3 2025, with the low at -$92.1 million in Q4 2025.
• The 4-year median for Research & Development is $10.5 million (2023), against an average of -$182636.4.
• Peak annual rise in Research & Development reached 130.43% in 2024, while the deepest fall reached 437.94% in 2024.
• Bicara Therapeutics' Research & Development stood at $10.5 million in 2023, then tumbled by 437.94% to -$35.5 million in 2024, then sank by 159.55% to -$92.1 million in 2025, then surged by 100.11% to $100000.0 in 2026.
• Business Quant data shows BCAX's Research & Development at $100000.0 in Q1 2026, -$92.1 million in Q4 2025, and $33.0 million in Q3 2025.